Detalhe da pesquisa
1.
Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial.
Gastric Cancer
; 26(1): 123-131, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36066725
2.
ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer.
Future Oncol
; 18(32): 3563-3572, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36382554
3.
Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
Lancet Oncol
; 22(1): 85-97, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33357420
4.
Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer.
Br J Cancer
; 125(1): 38-47, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33828257
5.
Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study.
Breast Cancer Res Treat
; 187(2): 467-476, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33748921
6.
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
Lancet Oncol
; 21(4): 519-530, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32171426
7.
Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study.
Breast Cancer Res Treat
; 182(3): 689-697, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32564260
8.
Efficacy and Safety of Pertuzumab and Trastuzumab Administered in a Single Infusion Bag, Followed by Vinorelbine: VELVET Cohort 2 Final Results.
Oncologist
; 22(10): 1160-1168, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28592618
9.
Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results.
Breast Cancer Res
; 18(1): 126, 2016 12 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-27955684
10.
Neoadjuvant-adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial.
Nat Commun
; 15(1): 2153, 2024 Mar 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38461323
11.
Real-World First-Line Use of Pertuzumab With Different Taxanes for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Comparative Effectiveness Study Using US Electronic Health Records.
JCO Oncol Pract
; 19(7): 435-445, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37167571
12.
Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer.
Eur J Cancer
; 178: 70-81, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36410207
13.
HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial.
Clin Cancer Res
; 29(3): 571-580, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36413222
14.
Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study.
Breast
; 64: 151-158, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35487845
15.
Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial.
J Clin Oncol
; 40(25): 2946-2956, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35763704
16.
BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer.
Cancers (Basel)
; 14(11)2022 May 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35681574
17.
Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial.
Eur J Cancer
; 166: 219-228, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35313167
18.
Results of a Dose-Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Clin Pharmacol Drug Dev
; 10(10): 1142-1155, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33788415
19.
Impact of Dose Delays and Alternative Dosing Regimens on Pertuzumab Pharmacokinetics.
J Clin Pharmacol
; 61(8): 1096-1105, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33719071
20.
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.
J Clin Oncol
; 39(13): 1448-1457, 2021 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33539215